Skip to Main content Skip to Navigation
Journal articles

Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis

Sarah Demortiere 1 Audrey Rico 1, 2, 3 Adil Maarouf 1, 2, 3 Clémence Boutiere 1 Jean Pelletier 1, 2, 3 Bertrand Audoin 1, 2, 3
1 Pôle de Neurosciences Cliniques, Service de Neurologie, APHM, Hôpital de la Timone, Aix-Marseille University, Marseille, France
2 CRMBM - Centre de résonance magnétique biologique et médicale
3 CEMEREM - Centre d'Exploration Métabolique par Résonance Magnétique [Hôpital de la Timone - AP-HM]
Abstract : Background: Planning pregnancy in patients with active multiple sclerosis (MS) is highly challenging because treatment withdrawn may be associated with dramatic disease reactivation. Objective: To compare two strategies for women with active MS who were planning pregnancy: stopping natalizumab (1) at the end of the first trimester and (2) at conception. Methods: Standardized strategy for women with active MS was initiated in our department. Maintenance of natalizumab until the end of first trimester was recommended (“secured first trimester” (SFT)). When patients refused, they were advised to continue until conception (“secured conception” (SC)). Predictors of disease activity during pregnancy were assessed. Results: Forty-six pregnancies were prospectively followed (30 with SFT and 16 with SC). One congenital anomaly occurred in the SC group. The proportions of patients with relapse and disability progression during pregnancy were lower in the SFT than in the SC group (3.6% vs 38.5%, p < 0.005 and 3.6% vs 30.8%, p < 0.05, respectively). Predictors of relapse and disability progression during pregnancy were the time when natalizumab was stopped (conception vs end of first trimester) and the number of relapses during the year before natalizumab. Conclusion: Maintaining natalizumab during the first trimester may reduce the risk of disease reactivation during pregnancy in patients with active MS.
Document type :
Journal articles
Complete list of metadata
https://hal-amu.archives-ouvertes.fr/hal-03537416
Contributor : Jean-Philippe Ranjeva Connect in order to contact the contributor
Submitted on : Thursday, January 20, 2022 - 1:52:14 PM
Last modification on : Friday, April 1, 2022 - 3:56:01 AM

Identifiers

Collections

UNIV-AMU | CRMBM | CNRS

Citation

Sarah Demortiere, Audrey Rico, Adil Maarouf, Clémence Boutiere, Jean Pelletier, et al.. Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis. Multiple Sclerosis Journal, SAGE Publications, 2021, 27 (5), pp.712-718. ⟨10.1177/1352458520912637⟩. ⟨hal-03537416⟩

Export

BibTeX TEI DC DCterms EndNote Datacite

Share

Metrics

Record views

5